Our results on angiogenin and VEGF levels (Figure 5D–I) showed that the division of T2DM PRP into groups (nontoxic/toxic PRP or PRP of patients without/with DFU) is not eligible, and it reflects only the difference between the growth factors levels in T2DM PRP versus PRP of healthy donors. This evidence concerns the gene VEGFA and type 2 diabetes mellitus.